MK-767. Kyorin/Banyu/Merck

Curr Opin Investig Drugs. 2003 Apr;4(4):444-8.

Abstract

MK-767 (KRP-297, L-410198) is a peroxisome proliferator-activated receptor (PPAR) alpha and PPAR gamma agonist under development by Banyu, Kyorin and Merck for the potential treatment of diabetes. The compound is currently undergoing phase III trials in the US and phase I trials in Japan.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Contraindications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / chemical synthesis
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Hypoglycemic Agents / toxicity
  • Thiazoles / adverse effects
  • Thiazoles / chemical synthesis
  • Thiazoles / pharmacology
  • Thiazoles / therapeutic use*
  • Thiazoles / toxicity
  • Thiazolidines

Substances

  • Hypoglycemic Agents
  • Thiazoles
  • Thiazolidines
  • 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide